Euglycemic DKA (euDKA) as a presentation of COVID‐19

COVID‐19 in the setting of SGLT2 inhibitor use may precipitate euglycemic DKA separate from known acute viral illness and dehydration precipitants. There should be consideration of proactive discontinuation of these medications in these patients. COVID‐19 in the setting of SGLT2 inhibitor use may pr...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Clinical case reports 2021-01, Vol.9 (1), p.395-398
Hauptverfasser:	Dass, Bhagwan, Beck, Andrew, Holmes, Cody, Morton, Glenville
Format:	Artikel
Sprache:	eng
Schlagworte:	Acidosis Alcohol use Case Report Case Reports Coronaviruses COVID-19 Diabetes diabetes mellitus diabetes type 2 Diabetic ketoacidosis euglycemia Glucagon Glucose Hyperglycemia Illnesses Infections Insulin Metabolism Patients Severe acute respiratory syndrome coronavirus 2 type I diabetes mellitus
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	COVID‐19 in the setting of SGLT2 inhibitor use may precipitate euglycemic DKA separate from known acute viral illness and dehydration precipitants. There should be consideration of proactive discontinuation of these medications in these patients. COVID‐19 in the setting of SGLT2 inhibitor use may precipitate euglycemic DKA separate from known acute viral illness and dehydration precipitants. There should be consideration of proactive discontinuation of these medications in these patients.
ISSN:	2050-0904 2050-0904
DOI:	10.1002/ccr3.3540